Healix

A 3-Year Evaluation of Antibiotic Resistance Patterns in Gram-Negative Genitourinary Tract Infections Treated in Outpatient Infusion Centers (POICs)

Published December 4, 2021

Richard L. Hengel, MD
Brian S. Metzger, MD, MPH
H. Barry Baker, MD, FACP
John S. Adams, MD
Ramesh V. Nathan, MD, FIDSA
Rishi Bhattacharyya, MD
Richard M. Mandel, MD, FIDSA
Kimberly A. Couch, PharmD, MA, FIDSA, FASHP
Claudia P. Schroeder, PharmD, PhD
Lucinda J. Van Anglen, PharmD

View Abstract

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.

FacebookTwitterLinkedInarrow1arcsearchiconowdtnotfound